Association of SET8 rs16917496 polymorphism with cancer risk: a meta-analysis

Background: The association of the mir-502 binding site in the 3' untraslated region of SET8 rs16917496 polymorphism with cancer risk has been explored by previous studies, but the result is still uncertain. Materials and methods: We carried out an updated meta-analysis of fourteen articles (containing 2974 cases and 3142 controls) to obtain an assessment of the influence of the SET8 rs16917496 polymorphism with risk of cancer. Results: Overall, the results revealed that the SET8 rs16917496 polymorphism was statistically associated with the risk of cancer under heterozygous model (OR = 1.13, 95% CI: 1.01-1.27, P = 0.03), though no evidence of association was found of rs16917496 polymorphism with cancer risk in other four model (allele model: OR = 1.00, 95% CI: 0.85-1.18, P = 0.975; recessive model: OR = 0.85, 95% CI: 0.60-1.19, P = 0.346; dominant model: OR = 1.07, 95% CI: 0.87-1.32, P = 0.495; homozygous model: OR = 0.84, 95% CI: 0.56-1.26, P = 0.398). After stratifying the overall population into subgroup sorted by ethnicity, no significant correlation was observed of the rs16917496 with cancer risk among both Caucasian and Asian populations. Conclusion: These result indicated that the SET8 rs16917496 was a genetic susceptible risk factor for cancer, and rs16917496 could be used as a biomarker for estimating cancer risk in overall population.